Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients

Table 2

sCEACAM1 correlates with S100B. ELISA measurements of posttreatment sCEACACM1 and S100B yielded values that were divided relative to median levels into “low” and “high.” The correlations between the two resulted “low” subgroups, as well as between the two “high” subgroups, were tested and found to be significant (𝑃=0.02). Percentages in each cubical refer to sCEACACM1 (first row) or to S100B (second row).

	Low S100B; 𝑁=25	High S100B; 𝑁=23
Low CEACAM1; 𝑁=29	𝑁=19	𝑁=10
	65.5% (19/29)	34.5% (10/29)
	76% (19/25)	43.5% (10/23)
High CEACAM1; 𝑁=19	𝑁=6	𝑁=13
	31.6% (6/19)	68.4% (13/19)
	24% (6/25)	56.5% (13/23)